We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Liquid Biopsy Approach for Predicting Likely Relapse Following Treatment of Medulloblastoma in Children

By LabMedica International staff writers
Posted on 02 Nov 2021
Print article
Image: Example of gene duplication that has created a copy number variation. The chromosome now has two copies of this section of DNA, rather than one (Photo courtesy of Wikimedia Commons)
Image: Example of gene duplication that has created a copy number variation. The chromosome now has two copies of this section of DNA, rather than one (Photo courtesy of Wikimedia Commons)
A liquid biopsy technique that determines the level of cell-free DNA in cerebrospinal fluid (CSF) can be used to detect measurable residual disease (MRD) in children being treated for the malignant brain tumor medulloblastoma.

Nearly one-third of children with medulloblastoma die from the disease. Conventional drug response monitoring by imaging and CSF cytology remains challenging, while a biomarker for MRD has not been found. MRD, which is the major cause of disease relapse, is the label for the small number of cancer cells that remain in the patient during treatment, or after treatment when the patient is in remission.

Investigators at St. Jude Children’s Research Hospital (Memphis, TN, USA) recently reported that they had identified a biomarker for medulloblastoma MDR. To do this, they used a liquid biopsy technique to acquire samples of cell-free DNA from the patients’ CSF combined with low-coverage whole-genome sequencing, which characterized the type of mutation called genome-wide copy number variation.

For this study, they analyzed serial CSF samples collected from children with medulloblastoma (123 patients, 476 samples) enrolled in a prospective trial. Results revealed that MRD was detected at baseline in 85% and 54% of patients with metastatic and localized disease, respectively. The number of MRD-positive patients declined with therapy, yet those with persistent MRD had significantly higher risk of progression. Importantly, MRD detection by the liquid biopsy method preceded radiographic progression in half the patients who relapsed.

“We scan patients frequently for the first couple of years when they come off therapy, but unfortunately, by the time we see a recurrence on a scan there is already a lot of disease,” said senior author Dr. Giles Robinson, a neuro-oncologist at St. Jude Children’s Research Hospital. “Relapsed medulloblastoma harbors an incredibly poor prognosis and for many it is too late to cure. As a result, we sought a better way to determine whether a child is truly clear of disease at the time they come off therapy. With this test, we now know that if there is medulloblastoma cell-free DNA in the CSF at the end of therapy, then that patient is very likely to relapse. That gives us something we can act on, an opportunity to truly eradicate the disease before it has had a chance to relapse or re-emerge.”

The medulloblastoma MRD study was published in the October 21, 2021, online edition of the journal Cancer Cell.

Related Links:
St. Jude Children’s Research Hospital

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.